文献速递类风湿关节炎

美国风湿病学会/欧洲抗风湿病联盟类风湿关节炎缓解标准:2022年修订版

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.
PubMed 文献 · Ann Rheum Dis · 2022-10-24

基于四项比较生物改善病情抗风湿药与甲氨蝶呤或安慰剂的随机试验数据,验证将患者总体评估阈值提高至2 cm的Boolean2.0缓解标准,并验证暂定认可的指数型标准。结果显示Boolean2.0较Boolean1.0更多患者达到缓解且与SDAI/CDAI一致性更好,预测影像学和功能结局的价值未受损。ACR和EULAR认可该修订版Boolean定义及暂定认可的指数型标准。

要点

  • Boolean2.0将患者总体评估阈值从1 cm提高至2 cm,使早期和确立期RA缓解率均提高。
  • Boolean2.0与SDAI或CDAI缓解标准的一致性优于Boolean1.0,尤其在早期病程中。
  • Boolean2.0、SDAI和CDAI缓解标准预测影像学无进展和HAQ≤0.5的阳性似然比相似(3.8-4.3)。

核心结论

  • 使用Boolean2.0标准可将更多患者分类为达到缓解,并提高与指数型缓解标准的一致性,且不损害对影像学或功能结局的预测价值。
  • ACR和EULAR认可该修订版Boolean定义及先前暂定认可的指数型标准。

研究设计与样本

  • 研究使用四项比较生物改善病情抗风湿药与甲氨蝶呤或安慰剂的随机试验数据。
  • 共纳入2048例试验参与者,其中早期RA 1101例,确立期RA 947例。

主要发现

  • 治疗开始后6个月,使用Boolean2.0较Boolean1.0的缓解患者比例在早期RA从14.8%升至20.6%,在确立期RA从4.2%升至6.0%。
  • Boolean2.0与SDAI或CDAI缓解标准的一致性优于Boolean1.0,尤其在早期疾病中。
  • Boolean2.0、SDAI和CDAI缓解标准预测影像学无进展和HAQ评分≤0.5的阳性似然比相似(阳性LR 3.8-4.3)。
  • 省略PtGA(BooleanX)削弱了对良好功能结局的预测。

关键数值与推荐

  • Boolean2.0采用患者总体评估阈值2 cm(范围0-10 cm),原Boolean1.0阈值为1 cm。
  • 缓解标准包括基于Boolean和基于指数(SDAI和CDAI)两类。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent studies indicating that a higher threshold for the patient global assessment (PtGA) may improve agreement between the two sets of criteria, our goals were to externally validate a revision of the Boolean remission criteria using a higher PtGA threshold and to validate the provisionally endorsed index-based criteria. METHODS: We used data from four randomised trials comparing biological disease-modifying antirheumatic drugs to methotrexate or placebo. We tested the higher proposed PtGA threshold of 2 cm (Boolean2.0) (range 0-10 cm) compared with the original threshold of 1 cm (Boolean1.0). We analysed agreement between the Boolean-based and index-based criteria (Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI)) for remission and examined how well each remission definition predicted later good physical function (Health Assessment Questionnaire (HAQ) score≤0.5) and radiographic non-progression. RESULTS: Data from 2048 trial participants, 1101 with early RA and 947 with established RA, were included. The proportion of patients with disease in remission at 6 months after treatment initiation increased when using Boolean2.0 compared with Boolean1.0, from 14.8% to 20.6% in early RA and 4.2% to 6.0% in established RA. Agreement between Boolean2.0 and the SDAI or CDAI remission criteria was better than for Boolean1.0, particularly in early disease. Boolean2.0, SDAI, and CDAI remission criteria had similar positive likelihood ratios (LRs) to predict radiographic nonprogression and a HAQ score of ≤0.5 (positive LR 3.8-4.3). The omission of PtGA (BooleanX) worsened the prediction of good functional outcomes. CONCLUSION: Using the Boolean 2.0 criteria classifies, more patients as achieving remission and increases the agreement with index-based remission criteria without jeopardising predictive value for radiographic or functional outcomes. This revised Boolean definition and the previously provisionally endorsed index-based criteria were endorsed by ACR and EULAR.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis. 2022. PMID: 36280238. doi:10.1136/ard-2022-223413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。